The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

12 Oct 2017 10:58

RNS Number : 4478T
Realm Therapeutics PLC
12 October 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

REALM THERAPEUTICS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Placing of 66,396,485 shares

X

3. Details of person subject to the notification obligationiv

Name

SUSSEX TRADING COMPANY LTD

City and country of registered office (if applicable)

LONDON, UK.

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

10TH OCTOBER 2017

6. Date on which issuer notified (DD/MM/YYYY):

10TH OCTOBER 2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.18

0

5.18

6,048,880

Position of previous notification (if

applicable)

10.2

0

10.2

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD GBP0.10

6,048,880

5.18%

SUBTOTAL 8. A

6,048,880

5.18%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

STEWART NEWTON

 N/A

N/A

SUSSEX RESEARCH LTD

N/A

N/A

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

10th October 2017

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEANEAFSKXFEF
Date   Source Headline
18th Aug 20167:00 amRNSBlock listing Interim Review
17th Aug 20167:00 amRNSPuriCore Receives Two U.S. Patents
16th Jun 201611:39 amRNSResult of AGM
9th Jun 20167:00 amRNSCompletion of Pre-IND Meeting with FDA on PR022
27th May 20167:00 amRNSResolution reached with EPA
14th Apr 20167:00 amRNSAppointment of Dr. Christian Peters as CMO
31st Mar 20167:00 amRNSNotice of AGM
29th Mar 20163:11 pmRNSDirector Dealing
29th Mar 20167:00 amRNSGrant of Options
24th Mar 20163:22 pmRNSAnnual Financial Report
24th Mar 20167:00 amRNSFinal Results
1st Mar 20167:00 amRNSAppointment of Dr Simba Gill to the Board
19th Feb 20169:30 amRNSBlocklisting Interim Review
8th Feb 20167:00 amRNSStrategic Review and Trading Update
4th Jan 201610:21 amRNSHolding(s) in Company
21st Dec 20158:55 amRNSHolding(s) in Company
14th Oct 20155:13 pmRNSDirector Dealing
30th Sep 20156:08 pmRNSHolding(s) in Company
28th Sep 20157:00 amRNSDirector Dealings
23rd Sep 20157:00 amRNSHalf Yearly Report
19th Aug 20158:33 amRNSBlocklisting Interim Review
1st Jul 20157:00 amRNSChange of Registered Office
19th Jun 20157:00 amRNSBoard Changes
18th Jun 201511:00 amRNSResult of AGM
9th Jun 20155:02 pmRNSGrant of Options
19th May 20157:00 amRNSAppointment of Alex Martin as CEO
2nd Apr 20157:00 amRNSDirector Dealing
31st Mar 20157:00 amRNSFinal Results
30th Mar 201512:22 pmRNSHolding(s) in Company
19th Mar 20157:00 amRNSSigns Major Supermarket Deal
24th Feb 20157:00 amRNSTrading Update
17th Feb 20158:24 amRNSBlocklisting Interim Review
9th Jan 20157:00 amRNSHolding(s) in Company
23rd Dec 20148:00 amRNSCancellation - PuriCore Plc
23rd Dec 20147:00 amRNSPuricore commences trading on AIM
25th Nov 20147:00 amRNSStrategic and Operational Review Update
24th Nov 20142:03 pmRNSResult of General Meeting
7th Nov 20147:00 amRNSProposed listing changes and notice of GM
5th Nov 20147:00 amRNSPuriCore granted two U.S. patents
31st Oct 20147:00 amRNSInterim Management Statement
14th Oct 20147:00 amRNSPlanned Directorate Changes
12th Aug 201411:49 amRNSDirector Dealing
11th Aug 20147:00 amRNSBlocklisting Interim Review
8th Aug 20147:00 amRNSHalf Yearly Report
31st Jul 20141:51 pmRNSNotice of Results
11th Jul 20147:00 amRNSTrading Update and Strategic Review
1st Jul 20147:00 amRNSCompletes Sale of UK Endoscopy Business
23rd Jun 20147:00 amRNSBoard Changes
20th Jun 201410:59 amRNSResult of General Meeting
19th Jun 201411:49 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.